{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:48:25Z","timestamp":1793033305633,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2011 a working group of the European Society for the Study of Tourette syndrome (ESSTS) developed the first European Guidelines for Tourette syndrome (TS) published in the ECAP journal. After a decade ESSTS now presents updated guidelines, divided into four sections: Part I: assessment, Part II: psychological interventions, Part III: pharmacological treatment and Part IV: deep brain stimulation (DBS). In this paper, we summarise new developments described in the guidelines with respect to assessment and treatment of tics. Further, summary findings from a recent survey conducted amongst TS experts on these same topics are presented, as well as the first European patient representative statement on research. Finally, an updated decision tree is introduced providing a practical algorithm for the treatment of patients with TS. Interestingly, in the last decade there has been a significant shift in assessment and treatment of tics, with more emphasis on non-pharmacological treatments.<\/jats:p>","DOI":"10.1007\/s00787-021-01832-4","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T23:21:06Z","timestamp":1625872866000},"page":"377-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["European clinical guidelines for Tourette syndrome and other tic disorders: summary statement"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-7419","authenticated-orcid":false,"given":"Kirsten R.","family":"M\u00fcller-Vahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6160-9221","authenticated-orcid":false,"given":"Natalia","family":"Szejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3436-6903","authenticated-orcid":false,"given":"Cara","family":"Verdellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1873-7081","authenticated-orcid":false,"given":"Veit","family":"Roessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter J.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0335-984X","authenticated-orcid":false,"given":"Andreas","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-4118","authenticated-orcid":false,"given":"Danielle C.","family":"Cath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,10]]},"reference":[{"key":"1832_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.brs.2015.11.005","volume":"9","author":"JC Baldermann","year":"2016","unstructured":"Baldermann JC, Sch\u00fcller T, Huys D, Becker I, Timmermann L, Jessen F, Visser-Vandewalle V, Kuhn J (2016) Deep brain stimulation for Tourette-Syndrome: a systematic review and meta-analysis. Brain Stimul 9:296\u2013304","journal-title":"Brain Stimul"},{"key":"1832_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aap8757","author":"C Brainstorm","year":"2018","unstructured":"Brainstorm C, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, Malik R, Patsopoulos NA, Ripke S, Wei Z, Yu D, Lee PH, Turley P, Grenier-Boley B, Chouraki V, Kamatani Y, Berr C, Letenneur L, Hannequin D, Amouyel P, Boland A, Deleuze JF, Duron E, Vardarajan BN, Reitz C, Goate AM, Huentelman MJ, Kamboh MI, Larson EB, Rogaeva E, St George-Hyslop P, Hakonarson H, Kukull WA, Farrer LA, Barnes LL, Beach TG, Demirci FY, Head E, Hulette CM, Jicha GA, Kauwe JSK, Kaye JA, Leverenz JB, Levey AI, Lieberman AP, Pankratz VS, Poon WW, Quinn JF, Saykin AJ, Schneider LS, Smith AG, Sonnen JA, Stern RA, Van Deerlin VM, Van Eldik LJ, Harold D, Russo G, Rubinsztein DC, Bayer A, Tsolaki M, Proitsi P, Fox NC, Hampel H, Owen MJ, Mead S, Passmore P, Morgan K, Nothen MM, Rossor M, Lupton MK, Hoffmann P, Kornhuber J, Lawlor B, McQuillin A, Al-Chalabi A, Bis JC, Ruiz A, Boada M, Seshadri S, Beiser A, Rice K, van der Lee SJ, De Jager PL, Geschwind DH, Riemenschneider M, Riedel-Heller S, Rotter JI, Ransmayr G, Hyman BT, Cruchaga C, Alegret M, Winsvold B, Palta P, Farh KH, Cuenca-Leon E, Furlotte N et al (2018) Analysis of shared heritability in common disorders of the brain. Science. https:\/\/doi.org\/10.1126\/science.aap8757","journal-title":"Science"},{"key":"1832_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00787-011-0164-6","volume":"20","author":"DC Cath","year":"2011","unstructured":"Cath DC, Hedderly T, Ludolph AG, Stern JS, Murphy T, HartmannCzernecki AV, Robertson MM, Martino D, Munchau A, Rizzo R, Group EG (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment. Eur Child Adolesc Psychiatry 20:155\u2013171","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1832_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/jamapsychiatry.2014.2650","volume":"72","author":"ME Hirschtritt","year":"2015","unstructured":"Hirschtritt ME, Lee PC, Pauls DL, Dion Y, Grados MA, Illmann C, King RA, Sandor P, McMahon WM, Lyon GJ, Cath DC, Kurlan R, Robertson MM, Osiecki L, Scharf JM, Mathews CA (2015) Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiat 72:325\u2013333","journal-title":"JAMA Psychiat"},{"key":"1832_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","volume":"28","author":"JF Leckman","year":"1989","unstructured":"Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ (1989) The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566\u2013573","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1832_CR6","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00134-018-5293-7","volume":"44","author":"A Lundh","year":"2018","unstructured":"Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2018) Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Med 44:1603\u20131612","journal-title":"Intensive Care Med"},{"key":"1832_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jamaneurol.2017.4317","volume":"75","author":"D Martinez-Ramirez","year":"2018","unstructured":"Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, Porta M, Servello D, Meng FG, Kuhn J, Huys D, Baldermann JC, Foltynie T, Hariz MI, Joyce EM, Zrinzo L, Kefalopoulou Z, Silburn P, Coyne T, Mogilner AY, Pourfar MH, Khandhar SM, Auyeung M, Ostrem JL, Visser-Vandewalle V, Welter ML, Mallet L, Karachi C, Houeto JL, Klassen BT, Ackermans L, Kaido T, Temel Y, Gross RE, Walker HC, Lozano AM, Walter BL, Mari Z, Anderson WS, Changizi BK, Moro E, Zauber SE, Schrock LE, Zhang JG, Hu W, Rizer K, Monari EH, Foote KD, Malaty IA, Deeb W, Gunduz A, Okun MS (2018) Efficacy and safety of deep brain stimulation in Tourette syndrome: the international Tourette syndrome deep brain stimulation public database and registry. JAMA Neurol 75:353\u2013359","journal-title":"JAMA Neurol"},{"key":"1832_CR8","doi-asserted-by":"publisher","first-page":"e1680","DOI":"10.1212\/WNL.0000000000011610","volume":"96","author":"D Martino","year":"2021","unstructured":"Martino D, Schrag A, Anastasiou Z, Apter A, Benaroya-Milstein N, Buttiglione M, Cardona F, Creti R, Efstratiou A, Hedderly T, Heyman I, Huyser C, Madruga M, Mir P, Morer A, Mol Debes N, Moll N, M\u00fcller N, M\u00fcller-Vahl K, Munchau A, Nagy P, Plessen KJ, Porcelli C, Rizzo R, Roessner V, Schnell J, Schwarz M, Skov L, Steinberg T, Tarnok Z, Walitza S, Dietrich A, Hoekstra PJ (2021) Association of Group A streptococcus exposure and exacerbations of chronic tic disorders: a multinational prospective cohort study. Neurology 96:e1680\u2013e1693","journal-title":"Neurology"},{"key":"1832_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00787-011-0166-4","volume":"20","author":"KR Muller-Vahl","year":"2011","unstructured":"Muller-Vahl KR, Cath DC, Cavanna AE, Dehning S, Porta M, Robertson MM, Visser-Vandewalle V, Group EG (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. Eur Child Adolesc Psychiatry 20:209\u2013217","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1832_CR10","doi-asserted-by":"publisher","unstructured":"M\u00fcller-Vahl KR, Fremer C, Beals C, Ivkovic J, Loft H, Schindler C (2021) Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12-Week, Randomized, Controlled Study. Mov Disord. https:\/\/doi.org\/10.1002\/mds.28681","DOI":"10.1002\/mds.28681"},{"key":"1832_CR11","unstructured":"M\u00fcller-Vahl KRR, Veit; M\u00fcnchau, Alexander (2020) Tourette-Syndrom: H\u00e4ufig eine Fehldiagnose. Deutsche Aerzteblatt 117"},{"key":"1832_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.0000000000007467","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, Martino D, Muller-Vahl K, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M (2019) Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92:907\u2013915","journal-title":"Neurology"},{"key":"1832_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Okun MS, M\u00fcller-Vahl K, Martino D, Jankovic J, Cavanna AE, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M, Holler-Managan Y, Piacentini J (2019) Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 92:896\u2013906","journal-title":"Neurology"},{"key":"1832_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","volume":"20","author":"V Roessner","year":"2011","unstructured":"Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ, Group EG (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 20:173\u2013196","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1832_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/cap.2016.0026","volume":"27","author":"F Sallee","year":"2017","unstructured":"Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, van Beek A, Nyilas M, Carson W, Kurlan R (2017) Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette\u2019s disorder in children and adolescents. J Child Adolesc Psychopharmacol 27:771\u2013781","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1832_CR16","unstructured":"TEVA (2020) Teva announces registration trials of deutetrabenazine in pediatric patients with Tourette syndrome did not meet the primary endpoint"},{"key":"1832_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00787-011-0167-3","volume":"20","author":"C Verdellen","year":"2011","unstructured":"Verdellen C, van de Griendt J, Hartmann A, Murphy T, Group EG (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry 20:197\u2013207","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1832_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-0043-124872","volume":"52","author":"C Yang","year":"2019","unstructured":"Yang C, Hao Z, Zhang LL, Zhu CR, Zhu P, Guo Q (2019) Comparative efficacy and safety of antipsychotic drugs for tic disorders: a systematic review and Bayesian network meta-analysis. Pharmacopsychiatry 52:7\u201315","journal-title":"Pharmacopsychiatry"},{"key":"1832_CR19","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.4088\/JCP.12m08189","volume":"74","author":"HK Yoo","year":"2013","unstructured":"Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, Kim BN, Cho SC (2013) A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Clin Psychiatry 74:e772-780","journal-title":"J Clin Psychiatry"}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-021-01832-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-021-01832-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-021-01832-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T03:20:59Z","timestamp":1647919259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-021-01832-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,10]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1832"],"URL":"https:\/\/doi.org\/10.1007\/s00787-021-01832-4","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,10]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"KMV has received financial or material research support from EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978) DFG: GZ MU 1527\/3-1 and GZ MU 1527\/3-2, BMBF: 01KG1421, National Institute of Mental Health (NIMH), Tourette Gesellschaft Deutschland e.V. Else-Kr\u00f6ner-Fresenius-Stiftung, GW pharmaceuticals, Almirall Hermal GmbH, Abide Therapeutics, and Therapix Biosiences. She has received consultant's honoraria from Abide Therapeutics, Boehringer Ingelheim International GmbH, Bionorica Ethics GmbH, CannaMedical Pharma GmbH, Canopy Grouth, Columbia Care, CTC Communications Corp., Demecan, Eurox Deutschland GmbH, Global Praxis Group Limited, IMC Germany, Lundbeck, Sanity Group, Stadapharm GmbH, Synendos Therapeutics AG, and Tilray. She is an advisory\/scientific board member for CannaMedical Pharma GmbH, Bionorica Ethics GmbH, CannaXan GmbH, Canopy Growth, Columbia Care, IMC Germany, Leafly Deutschland GmbH, Sanity Group, Syqe Medical Ltd., Therapix Biosciences Ltd., and Wayland Group. She has received speaker\u2019s fees from Aphria Deutschland GmbH, Almirall, Cogitando GmbH, Emalex, Eurox Deutschland GmbH, Ever pharma GmbH, Meinhardt Congress GmbH, PR Berater, Spectrum Therapeutics GmbH, Takeda GmbH, Tilray, Wayland Group. She has received royalties fromDeutsches \u00c4rzteblatt, Der Neurologie und Psychiater, Elsevier, Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, and Kohlhammer. She served as a guest editor for Frontiers in Neurology on the research topic \u201cThe neurobiology and genetics of Gilles de la Tourette syndrome: new avenues through large-scale collaborative projects\u201d, is an associate editor for \u201cCannabis and Cannabinoid Research\u201d and an Editorial Board Member of \u201cMedical Cannabis and Cannabinoids\u201d und \u201cMDPI-Reports\u201d and a Scientific board member for \u201cZeitschrift f\u00fcr Allgemeinmedizin\u201d. NSZ has no conflicts to declare. DC has received financial support from EU (FP7-HEALTH-2011 No. 278367; FP7-PEOPLE-2012-ITN No. 316978), from VCVGz, and from Tourette Association of America. AH has received financial or material research support from the Association Fran\u00e7aise pour le syndrome de Gilles de la Tourette (AFSGT). He has received consultant's honoraria from Lundbeck and Noema Pharma. VR has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma, and support for research from Shire Pharmaceuticals and Novartis. He has carried out clinical trials in cooperation with the Novartis, Shire, Servier and Otsuka companies. PJH has received a honorarium for an advisory board meeting of Shire. NSZ and CV have no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}